Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05389267 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 7, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jun 15, 2023 to Dec 31, 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jun 30, 2023 to Dec 31, 2024
    • Site details revised
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 3, 2022 to Jul 5, 2022
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study purpose is to evaluate the safety of T4090.
Trial Details
NCT Number NCT05389267
Lead Sponsor Laboratoires Thea
Conditions
(from sponsor)		 Glaucoma, Ocular Hypertension
Related terms Glaucoma, Ocular Hypertension
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov